'

Subscribe to Hematology News

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myeloma therapies raise cardiovascular risks

Publish date:: March 1, 2019

Key clinical point: Drugs commonly used to treat multiple myeloma carry cardiovascular risks that should be carefully monitored.

Major finding: Cardiovascular adverse events occurred in 33 of the 65 patients (51%) randomized to carfilzomib, compared with 5 of 30 patients (17%) assigned to bortezomib.

Study details: The ongoing PROTECT trial enrolled 95 patients with relapsed multiple myeloma and randomized them to receive carfilzomib or bortezomib.

Disclosures: The PROTECT study is sponsored by Millennium Pharmaceuticals. Dr. Cornell reported having no financial disclosures.

Citation:

REPORTING FROM ACC CARDIO-ONCOLOGY

This Week's Must Reads

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,

Neoadjuvant immunotherapy combo produces high response rate in melanoma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Must Reads in Lymphoma & Plasma Cell Disorders

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,

New cancer drugs may have saved more than 1.2 million Americans,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,

Socioeconomic factors affect survival of multiple myeloma patients,